RegeneRx Biopharmaceuticals, Inc. Receives Notice of Allowance on Two Cardiac-Related Patent Applications

ROCKVILLE, Md.--(BUSINESS WIRE)--RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.